Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics

Neuropsychopharmacology

Volumn 17, Issue 3, 1997, Pages 141-150

  Malhotra, Anil K ^a   Pinals, Debra A ^a   Adler, Caleb M ^a   Elman, Igor ^a   Clifton, Allan ^a   Pickar, David ^a   Breier, Alan ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Cognition; Ketamine; NMDA; Psychosis; Schizophrenia

Indexed keywords

KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HALLUCINATION; HUMAN; MALE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

EID: 0030749913     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(97)00036-5     Document Type: Article

References (30)

1. Allen RM, Young SJ (1978): Phencyclidine-induced psychosis. Am J Psychiatry 135:1081-1084
2. Anis NA, Berry SC, Burton NR, Lodge D (1983): The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79:565-575
3. Ban TA, Lohrenz JJ, Lehmann HE (1961): Observations on the action of sernyl - a new psychotropic drug. Can J Psychiatry 6:150-157
4. Byrd LD, Standish LJ, Howell LL (1987): Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs. Eur J Pharmacol 144:331-341
5. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS (1962): Comparison of phenylcyclidine hydrochloride (Sernyl) with other drugs. Arch Gen Psychiatry 6:395-397
6. Cohen ML, Chan SL, Bhargava HN, Trevor AJ (1974): Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol 23:1647-1652
7. Crosby G, Crane AM, Sokoloff L (1982): Local changes in cerebral glucose utilization during ketamine anesthesia. Anesthesiologist 56:437-443
8. Davies BM, Beech HR (1960): The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Ment Sci 106:912-924
9. Hammer RP, Herkenham M (1983): Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J Comp Neurol 220:396-404
10. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308
11. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers Jr MB, Charney DS (1994): Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214
12. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995): Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
13. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959): Study of a new schizophrenomimetic drug-sernyl. Arch Neurol Psychiatry 81:363-369
14. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A (1996): NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307
15. Moretti RJ, Hassan SZ, Goodman LI, Meltzer HY (1984): Comparison of ketamine and thiopental in healthy volunteers: Effects on mental status, mood, and personality. Anesth Analg 63:1087-1096
16. Olney JW, Labruyere J, Price MT (1989): Pathological changes induced in cerebrocortical neurons by phenylcyclidine and related drugs. Science 244:1360-1362
17. Olney JW, Farber NB (1995): Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007
18. Overall JE, Gorham DR (1962): The brief psychiatric rating scale. Psychol Rep 10:799-812
19. Oye I, Hustveit O, Moberg ER, Pausen O, Skoglund LA (1991): The chiral forms of ketamine as probes for NMDA receptor function in humans. In Kameyama T, Nabeshima T, Domino EF (eds), NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior. Ann Arbor, Michigan, NPP Books, pp 381-389
20. Pandit SK, Kothary SP, Kumar SM (1980): Low dose intravenous infusion technique with ketamine. Anaesthesia 35:669-675
21. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D (1959): Comparison of Sernyl with other drugs. A. M. A. Arch Gen Psychiatry 1:651-666
22. Rothman S (1988): Noncompetitive N-methyl-D-aspartate antagonists affect multiple ionic currents. J Pharmacol Exp Ther 246:137-142
23. Schorn TOF, Whitman JG (1980): Are there long-term effects of ketamine on the central nervous system? Br J Anaesth 52:967-968
24. Smith DJ, Azzaro AJ, Zaldivar SB, Palmer S, Lee HS (1981): Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology 20: 391-396
25. Smith DJ, Pekoe GM, Martin LL, Coalgate B (1980): The interaction of ketamine with the opiate receptor. Life Sci 26:789-795
26. Spitzer RL, Williams JBW, Gibbon M, First MB (1990): Structured clinical interview for DSM-III-R-patient edition (SCID-P, Version 1.0). Washington, DC: American Psychiatric Press
27. Weingartner HJ, Hommer D, Lister RG, Thompsom K, Wolkowitz O (1992): Selective effects of triazolam on memory. Psychopharmacology 106:341-345
28. Weingartner H, Grafman J, Boutelle W, Kayne W, Martin PR (1983a): Forms of memory failure. Science 221:380-382
29. Weingartner H, Rudorfer MV, Buchsbaum MS, Linnoila M (1983b): Effects of serotonin on memory impairments produced by ethanol. Science 221:472-473
30. Weingartner H, Langer D, Grice J, Rapoport J (1982): Acquisition and retrieval of information in amphetamine-treated hyperactive children. Psychiatry Res 6:21-29